Pharma Journalist -

Eli Lilly and Company has acquired 4E Therapeutics, a privately held neuroscience biotechnology company focused on developing next-generation therapies for chronic pain, strengthening…
Read More...

Simulations Plus, a leading provider of model-informed and AI-enabled drug development software and services, has agreed to be acquired by healthcare-focused investment firm Altaris in…
Read More...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the U.S. Food and Drug Administration (FDA) have announced a new liaison programme aimed at strengthening…
Read More...

SpliSense has secured a funding commitment of up to $13 million from the Cystic Fibrosis Foundation to support the continued clinical development of its lead investigational therapy,…
Read More...

AviadoBio has expanded its partnership with King’s College London, securing exclusive rights to apply the vMiX™ RNA interference (RNAi) gene-silencing platform across all human…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in Jacksonville, Florida, to expand its Vision business operations and strengthen domestic manufacturing,…
Read More...

Alkermes plc has received significant regulatory recognition for its investigational sleep disorder therapy alixorexton, with health authorities in both the United States and Europe…
Read More...

Chiesi Group has completed its acquisition of KalVista Pharmaceuticals, marking a significant expansion of its rare diseases business and adding a recently approved hereditary…
Read More...

Johnson & Johnson has reported positive results from the Phase 2/3 ENERGY study evaluating IMAAVY® (nipocalimab-aahu) in patients with warm autoimmune hemolytic anemia (wAIHA), a…
Read More...

GSK has received a significant regulatory boost for its investigational efforts in rare diseases after both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency…
Read More...